Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYK-224 in healthy Japanese adults
NCT05405543Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986435 in hypertrophic cardiomyopathy (HCM) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 72 days, Time of maximum observed concentration up to 72 days and 1 more. Started Jul 2022; status: completed.
02
Drugs
BMS-986435
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05405543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405543.